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ABSTRACT Rod and cone photoreceptors are specialized retinal neurons that have a fundamental role in
visual perception, capturing light and transducing it into a neuronal signal. Aberrant functioning of rod and/
or cone photoreceptors can ultimately lead to progressive degeneration and eventually blindness. In man,
many rod and rod-cone degenerative diseases are classiﬁed as forms of retinitis pigmentosa (RP). Dogs also
have a comparable disease grouping termed progressive retinal atrophy (PRA). These diseases are generally
due to single gene defects and follow Mendelian inheritance.We collected 51 DNA samples from Miniature
Schnauzers affected by PRA (average age of diagnosis 3.9 61 years), as well as from 56 clinically normal
controls of the same breed (average age 6.6 62.8 years). Pedigree analysis suggested monogenic auto-
somal recessive inheritance of PRA. GWAS and homozygosity mapping deﬁned a critical interval in the ﬁrst
4,796,806 bp of CFA15. Whole genome sequencing of two affected cases, a carrier and a control identiﬁed
two candidate variants within the critical interval. One was an intronic SNV in HIVEP3, and the other was a
complex structural variant consisting of the duplication of exon 5 of the PPT1 gene along with a conversion
and insertion (named PPT1dci). PPT1dci was conﬁrmed homozygous in a cohort of 22 cases, and 12 more
cases were homozygous for the CFA15 haplotype. Additionally, the variant was found homozygous in
6 non-affected dogs of age higher than the average age of onset. The HIVEP3 variant was found hetero-
zygous (n = 4) and homozygous wild-type (n = 1) in cases either homozygous for PPT1dci or for the mapped
CFA15 haplotype. We detected the wildtype and three aberrant PPT1 transcripts in isolated white blood
cell mRNA extracted from a PRA case homozygous for PPT1dci, and the aberrant transcripts involved
inclusion of the duplicated exon 5 and novel exons following the activation of cryptic splice sites. No
neurological signs were detected among the dogs homozygous for the PPT1dci variant. Therefore, we
propose PPT1dci as causative for a non-syndromic form of PRA (PRAPPT1) that shows incomplete penetrance
in Miniature Schnauzers, potentially related to the presence of the wild-type transcript. To our knowledge,













Rod and cone photoreceptors are specialized retinal neurons that have a
fundamental role in visual perception, capturing light and transducing it
into a neuronal signal. These light-sensitive cells are located adjacent to
the retinal pigment epithelium (RPE), a cell layer that is vital for the
maintenance and survival of photoreceptors. Aberrant functioning or
altered development of rod and/or cone photoreceptors (and of their
synaptic connections to secondorder neurons) or of the RPEoften leads
to dysfunction, progressive retinal degeneration and eventual blindness.
Sequence variants in more than 300 genes and loci are associated
to retinal degeneration in Homo sapiens (RetNet: https://sph.uth.edu/
RETNET/ 2018), and an increasing number of comparable diseases
have been described in non-human mammals. The latter can serve as
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valuable models for retinal disease gene discovery as they provide in-
formation regarding the precise molecular players and pinpoint the
speciﬁc molecular mechanisms related to the severity and onset of
the disease (Baehr and Frederick 2009, Miyadera et al. 2012). Large
animal models of inherited retinal diseases have also proven useful in
guiding the development of therapies that can then be transitioned to a
clinical setting (Petit et al. 2016, Aguirre 2017).
In humans, many rod and rod-cone degenerative diseases are
classiﬁed under the term retinitis pigmentosa (RP), a grouping that
includes known and suspected diseases inherited as autosomal domi-
nant, recessive or X-linked, as well as those of unknown mode of
inheritance, which are referred to as simplex. Dogs suffer from a
comparable group of diseases termed progressive retinal atrophy
(PRA), and these diseases generally follow Mendelian inheritance,
usually in an autosomal recessive manner - see for review: (Miyadera
et al. 2012, Downs et al. 2013, Winkler et al. 2013, Downs et al. 2014;
Svensson et al. 2016; Chew et al. 2017). Less frequent are those inherited
as autosomal dominant (Kijas et al. 2002; Kijas 2003) or X-linked
(Zhang et al. 2002; Kropatsch et al. 2016).
Photoreceptor dysplasia in Miniature Schnauzers, a more speciﬁc
phenotypewithin thePRAgroup,was initially reportedas an early-onset
autosomal recessive disease characterized by abnormal development of
rods and cones followed by rapid progression of degeneration. Breeding
studies supported autosomal recessive inheritance with a high degree of
statistical signiﬁcance (Parshall et al. 1991). Candidate gene studies
excluded the more obvious photoreceptor-speciﬁc/enriched candidates
(Zhang et al. 1999) including a phosducin sequence variant (Zhang
et al. 1998) that subsequently was found to not be disease-associated
(Aguirre, unpublished information).
After identifying mutations in RPGR as responsible for X-linked
PRA, we examined the breed origins of the XLPRA2 microdeletion
found in mongrel-derived dogs in our research colony. As the research
colonywas intentionally outbred to increase polymorphisms for linkage
mapping of disease (Acland et al. 1998; Aguirre and Acland 2006) we
analyzed for the XLPRA2 microdeletion in a subset of dogs from each
of the breeds that contributed to the colony population at the time;
among these were included the extant population of photoreceptor
dysplasia affected dogs together with archival DNA samples. This anal-
ysis conﬁrmed the presence of the RPGR:c. 1084–1085delGA variant in
hemizygous state in all affected male dogs, and in heterozygous state in
all obligate female carriers (Zhang et al. 2002). A review of the pheno-
types of dogs used for the breeding studies in the original publication
(Parshall et al. 1991) indicated that XLPRA2 carrier females were clin-
ically affected, but had a milder disease phenotype than hemizygous
males, hence the misinterpretation of the breeding studies that indi-
cated autosomal recessive inheritance. The disease, indeed, is X-linked
semi-dominant, a feature also found in some X-linked RP human
families with RPGR variants (Rozet et al. 2002).
The X-linked retinal degeneration inMiniature Schnauzers, termed
Type A PRA, is associated with a c.1084–1085delGA in RPGR (Zhang
et al. 1999). A commercial test for this variant was offered (OptiGen,
LLC; http://www.optigen.com/opt9_test_a_pra.html). It soon became
clear that Type A PRA was an extremely rare disorder in the breed; in
the 17 years the test has been available, not a single case of the disease
was found out of 375 samples tested. This prompted the company to
provide free testing for Miniature Schnauzers, as well as other dog
breeds, diagnosed with retinal degeneration. DNA from those Minia-
ture Schnauzers provided the samples used in the current study aimed
at the identiﬁcation of additional genetic variants causing PRA in the
breed.
MATERIALS AND METHODS
Sample collection and phenotype assessment
Blood samples were obtained from 107Miniature Schnauzers, 51with a
retinal degeneration compatible with a diagnosis of PRA, and 56 non-
affected controls; all dogs were tested and found negative for Type A
PRA. The average age of diagnosis for the cases was3.961 years, the
average age of examination for controls was6.662.8 years. (Table 1).
Samples were collected using standard clinical venipuncture techniques
with full consent of the owners. The majority of these dogs resided in
the United States, but additional dogs from Europe were also evaluated.
In addition to the dogs clinically ascertained by one of the authors
(GDA), the clinical evaluations of all the cases and controls were made
by board certiﬁed veterinary ophthalmologists in North America
(ACVO diplomates) and in Europe (ECVO diplomates), or accredited
eye specialists. All examinations were done after pharmacologic my-
driasis by indirect ophthalmoscopy and biomicroscopy as stipulated by
the ACVO and ECVO guidelines for screening eye examinations. For a
small subset of dogs fundus photographs were also available. Included
with the blood samples were the eye examination records, clinical
ﬁndings as well as, where possible, pedigree information. The clinical
information provided with all samples was reviewed by an ACVO
board certiﬁed veterinary ophthalmologist (GDA) prior to inclusion
in the study.
SNP genotyping
DNA was extracted with the Illustra DNA extraction kit BACC2 (GE
Healthcare) following manufacturer’s instructions. The ﬁrst round of
genotyping was carried out using the 48,341 marker Affymetrix canine
SNP array. We genotyped 53 dogs, 24 cases and 29 controls. After a
preliminary GWAS run, we then genotyped 27 dogs on the Illumina
CanineHD Beadchip that included 173,661 evenly distributed SNPs. Of
the 27 dogs genotyped on the second round, 11 (9 cases and 2 controls)
had already been genotyped in the Affymetrix SNP chip. The remaining
16 dogs consisted of 8 additional cases and 8 additional controls (therefore
32 cases and 37 controls in total, Table 1). All SNP genotypingwas carried
out using standard protocols as recommended by the manufacturer.
Genome-wide association
To carry out the GWAS, we merged the Illumina and Affymetrix data
through the “–merge” and “–extract” commands with PLINK 1.9
(Chang et al. 2015). Then, we extracted SNPs with a genotyping
rate.90% (“–geno 0.1”).We used BEAGLE3 (Browning and Browning
2007) to impute the missing SNPs, removed duplicate animals with
PLINK (“–exclude”), and ultimately created the ﬁnal dataset of 46,063
markers. This dataset was used for GWAS using the GenABEL package
and the R Studio integrated development environment (Aulchenko et al.
2007). As a preliminary step for each analysis, we used standard quality
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control settings to removemarkers and individuals with call rates,90%
from the analysis.We also removedmarkers withminor allele frequency
(MAF) ,5%, and markers strongly deviating from Hardy-Weinberg
equilibrium. Analysis of the pedigrees and breeding of the dogs in our
cohort suggested that that the population is slightly stratiﬁed. This anal-
ysis was followed by mixed model association study as designed in the
GenABEL package. The Manhattan plot was analyzed searching for
suggestive or associated peaks.
Homozygosity mapping and phasing
The GWAS analysis was followed by a homozygosity mapping approach
in order to identify extended intervals of homozygositywith shared alleles
as well as ﬁne-map the region containing the responsible gene/genetic
variant. Individuals and SNPswere selected using the commands “–keep”
and “–extract”, while ﬁnal ﬁles were generated through the “–merge”
command. Homozygosity analysis was performed on all cases using
the commands “–dog”, “–homozyg” and “–homozyg-group”, on the
merged dataset. We used BEAGLE3 (Browning and Browning 2007)
to phase the candidate chromosome and to look at the haplotypes of
cases and controls. As the GWAS analysis pointed to a suggestive asso-
ciation peak in CFA15, we focused on this chromosome. The CFA15 ﬁle
for BEAGLEwas preparedwith PLINK 1.9 using the “–beagle” and “–chr
15” commands. The haplotypes were visualized in Microsoft Excel.
Remapping
Since the SNPchipdatawere basedon theCanFam2.0 reference, and the
mapping of the targeted sequencing andwhole genome sequencing data
were carried out against the CanFam3.1 reference, we used the NCBI
“remap” function (https://www.ncbi.nlm.nih.gov/genome/tools/remap/)
to convert the dataset based on CanFam2.0.
Targeted sequencing
For targeted sequencing of the candidate region, we selected 6 PRA affected
dogs(agesrangingfrom2to4yearsold),and4unaffecteddogs(agesranging
from 3 years old to 11). For all 10 dogs, custom sequencing libraries were
designed through Agilent SureDesign website (https://earray.chem.agilent.
com/suredesign/), and biotinylated probes were used to capture DNA
fragments in the candidate region with above 60% coverage. The custom
sequencing paired-end libraries were prepared using Agilent SureSe-
lectXT2 Target Enrichment System, and then sequenced by Illumina
HiSeq2000 with a 300 bp insert size. The initial quality of the raw sequenc-
ing was checked by FastQC program (Brown et al. 2017). To obtain high
quality variant calls, we followed the best practices guides for the most
recent Genome Analysis Tool Kit (GATK) (McKenna et al. 2010). Specif-
ically, raw reads were mapped to the dog reference genome CanFam3.1
using Burrows-Wheeler Aligner (BWA) v0.7.10 (Li and Durbin 2009),
n = 8 threads. Duplicated reads were removed by Picard tools (https://
broadinstitute.github.io/picard/). The unique aligned reads went through a
local realignment to correct mismatched bases surrounding INDELs, and
the base quality scores were recalibrated based on an empirically accurate
per-base error model. BAM ﬁles containing the cleaned reads were ana-
lyzed byGATKHaplotypeCaller inwhich variant callingwas strictly forced
into the candidate region. Low quality variants were ﬁltered based on a set
of hardﬁlters: (1) variant quality scores normalized by coverage (QD),10;
(2) overall mapping quality of reads (MQ) ,40 and (3) strand bias
(FS) .60.0. Variant calls with Mendel errors were removed by PLINK
(Purcell et al. 2007). The above steps yielded 2,829 variants for downstream
analysis. Out of these 10 dogs, 4 were also genotyped by Illumina arrays,
we compared genotypes overlapping between two platforms. We
found that percentages of consistent genotypes were . 96% across
4 samples, indicating a high calling accuracy of targeted sequencing
analysis.
Whole genome sequencing
Four Illumina TruSeq PCR free DNA libraries with a 350 bp insert size
were prepared. The sequenced dogs were selected as two cases (homo-
zygous for the CFA15 haplotype), one obligate carrier (parent) and a
grand-parent. The cases were among those selected for the targeted
sequencing. HiSeq2500 paired-end reads (2x 100 bp)were collected; the
fastq ﬁles were created using Casava 1.8. A total of 1,010,526,513 100 bp
paired-end reads were collected for the four dogs (250million per dog
corresponding to an average 15x coverage of the genome). The paired-
end reads were then mapped to the dog reference genome CanFam3.1,
and the reads aligned using Burrows-Wheeler Aligner (BWA) version
0.5.9-r16 (Li and Durbin 2009) with default settings. The SAM ﬁle
generated by BWA was then converted to BAM and the reads
sorted by chromosome using samtools (Li et al. 2009). The PCR
n Table 1 Summary table of the dogs involved in the project, and how many were genotyped
with each SNP chip platform. Average age of diagnosis, and average age of the controls are also
reported
Affected Miniature Schnauzers 51
Genotyped 32
Homozygous CFA15 Haplotype 22
Not Homozygous for CFA15 Haplotype 10
Homozygous CFA15 Haplo in Illumina data 17
Homozygous CFA15 Haplo in Affymetrix data 12
In both 7
No SNP chip genotype 19
Non-affected Miniature Schnauzers 56
Genotyped 37
Heterozygous CFA15 haplotype 8
No CFA15 haplotype 29
No SNP chip genotype 19
Homozygous PPT1dci 6
 Average age of diagnosis: 3.9 61.0 years.
Average age of the controls: 6.6 62.8 years.
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duplicates were marked using Picard tools (http://sourceforge.net/
projects/picard/).
Variant discovery
The GATK version 2.4.9 program (McKenna et al. 2010) was was used
for variant calling of aligned data, using the uniﬁed genotyper module
of GATK. The variant data for each sample was obtained in variant call
format (vcf, version 4.0), as were raw calls for all samples and sites
ﬂagged using the standard variant ﬁltration module of GATK. Variant
ﬁltration was carried out, following the best practice documentation of
GATK version 4. SnpEff software (Cingolani et al. 2012) together with
the CanFam3.1 assembly was used to predict the functional effects of
the variants detected. In addition, the Delly2 program (Rausch et al.
2012) was used to detect structural variants in the four BAM ﬁles, and
to validate for suspected variants in a cohort of controls. The com-
mands for deletions, insertions, inversion and duplications were all
executed separately. The analysis focused on the candidate region.
In order to avoid missing large inserts, deletions and false positives,
all the variants detected were also compared within the candidate
region using 192 control genomes (see File_S1, European Nucleo-
tide Archive); note that in File_S1 Miniature Schnauzers are iden-
tiﬁed as ’Zwergschnauzer’.
PCR and Sanger sequencing
The PPT1 conversion (g.2,874,661_2,875,048con2,877,563-2,877,607inv,
see below) was veriﬁed in all the available cases and carrier dogs by
re-sequencing of targeted PCR products using Sanger sequencing. PCR
primers were designed using PRIMER3 (Untergasser et al. 2012) after
masking repetitive regions in the target region with RepeatMasker
(http://www.repeatmasker.org/) and provided by Integrated DNA Tech-
nologies. A standard set of primers was designed for theHIVEP3 intronic
variant (g.1,432,293G.A) in order to genotype it. Additional steps were
required in order to characterize the whole PPT1 variant (PPT1dci, see
below). Initially, because of the difﬁcult nature of the region, three long
PCR primers were designed in order to amplify the borders of the du-
plication (SequalPrep Long PCR, Thermo Fisher). The primers were two
pairs. Each pair had the same common forward primer, and a different
reverse primer. This resulted in a total of two distinct products (LF and
LR1; LF and LR2, see File_S2): a longer 4368 fragment and a shorter
3641 fragment. In order to examine the PPT1 exon 5 duplication variant,
we ﬁrst designed a PCR with primers targeted at the boundaries of the
duplicated region (see the B1F, B1R, B2F, and B2R primers in File_S2). A
speciﬁc primer set was designed to sequence the deleted interval (GF and
GR). A complete characterization of the variant required Sanger sequenc-
ing of the long PCR products with B1R, B2F, GF, GR, LF, LR1 and LR2.
As a ﬁnal step, in order to obtain an easily reproducible marker for
detection of the variant, we carefully analyzed the BAM ﬁle and iden-
tiﬁed two consecutive variants falling within the duplicated interval:
g.2,872,023delAG and g.2,872,103G . A (File_S5), and used them to
genotype the remaining cases. To further validate these markers, we
conﬁrmed the presence (either in homozygosity or heterozygosity) of
the conversion (g.2,874,661_2,875,048con2,877,563-2,877,607inv) with
the GF and GR primers (File_S2), targeted on the deleted interval. Such
primer pair produces a 538 bp fragment.
PCR was carried out with AmpliTaqGold360Mastermix (Life Tech-
nologies), and theproductswere sequencedusing thePCRprimersonan
ABI 3730 capillary sequencer (Life Technologies) after treatment with
exonuclease I (N.E.B.) and rAPid alkaline phosphatase (Roche). PCR
products were run on 1% agarose gel with 0.5mg/ml ethidiumbromide.
Sequence data were analyzed using Sequencher 5.1 (GeneCodes).
Transcript characterization
Because of the almost ubiquitous expressionofPPT1, RNAwas extracted
from the blood of a PPT1dci –homozygous case using the GeneJET
RNA Puriﬁcation Kit (Thermo Fisher). Reverse transcription was
carried out with Superscript III as described by the manufacturer
(Thermo Fisher), and PCR was carried out using AmpliTaqGold360-
Mastermix as described above. The primers were designed in order to
span the exon 4 to exon 6 interval (File_S2). The PCR products were
sequenced as above. The products were ligated to TOPO-TA cloning
plasmids pCRII (Thermo Fisher), as described by the manufacturer,
and the resulting vector was used to transform competent cells. The
colonies grown overnight were collected with a pipette tip, and lysed
in 20ml of dH2O. Such solution was used as a template for sequencing
with the same primers used for the cDNA exonic ampliﬁcation.
The HIVEP3 mRNA was annotated using SPLIGN (https://www.
ncbi.nlm.nih.gov/sutils/splign/splign.cgi) with the human transcript
NM_024503.4 as template.
TPM calculation
In order to have additional information concerning the tran-
script expression for HIVEP3 (ENSCAFT00000004055) and PPT1
(ENSCAFT00000038806) in retinal tissue, we decided to search in
three different canine retinal RNAseq datasets from outcrossed dogs
that are not Miniature Schnauzers were used. The dataset consisted of
11, 7 and 9 dogs, used in different projects carried out in our group.
Using the RNA-seq analysis software Kallisto (Bray et al. 2016), we
calculated the average tpm (transcript per million) for the HIVEP3
and PPT1 canine transcripts within all three datasets.
Data availability
File_S1: List and accession numbers of the 196 genomes of the study
available in the European Nucleotide Archive. File_S2 – Primers used
in the study. File_S3 –Orientation of the 45 bp interval copy. File_S4 –
Targeted sequencing results for the region. File_S5 – Detail of the
markers situated within the repeated region. File_S6 – The four tran-
scripts detected by cloning and sequencing. File_S7 – Alignment of
the wild type and mutant predicted protein. SNPchip and Targeted
sequencing data are available in the Targeted_Sequencing_SNPchip.
Murgiano ﬁle. Supplemental material available at Figshare: https://
doi.org/10.25387/g3.6830633 and https://doi.org/10.25387/g3.6836858.
RESULTS
Phenotypic characterization of a new PRA form in
Miniature Schnauzers
Clinical examination of Miniature Schnauzers, and the archiving of
blood samples for molecular studies continued after publication of the
disease characterization and genetic analysis of photoreceptor dysplasia
(Parshall et al. 1991). Once the mutation responsible for XLPRA2,
RPGR:c.1084–1085delGA, was identiﬁed (Zhang et al. 2002), samples
from all RPGR normal Miniature Schnauzer dogs diagnosed with PRA
were archived. This resulted in 51 affected dogs with a presumably
novel form of PRA. Based on the limited number of cases examined
by one of the authors (GDA), PRA-affected dogs were clinically indis-
tinguishable from the earlier described photoreceptor dysplasia cases
(Parshall et al. 1991). Clinical examinations using biomicroscopy and
indirect ophthalmoscopy showed that affected dogs were normal when
examined at 10 months of age or earlier. Subsequently, fundus changes
indicative of PRA developed. By 3 years of age, affected dogs showed
advanced retinal disease. They had slow and incomplete pupillary light
reﬂexes, and showed poor vision in familiar surroundings or preferred
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to be in a crate and not moving around. Comments were made on the
clinical records of 3-year-old dogs examined by one of the authors
(GDA) noted ’Fundus typical of photoreceptor dysplasia for age’.
Fundus abnormalities at3 years of age were characteristic of mid-
stage disease (Parshall et al. 1991), consisted of marked attenuation or
loss of retinal vessels, diffuse hyperreﬂectivity and ridging of the tapetal
region (an indication of retinal thinning) and RPE loss and pigment
migration in the non-tapetal regions of the eye (Figure 1). Cataracts
were not present at this time. Progression to end-stage retinal atrophy
and blindness occurred with age, although we could not specify the age
when these changes occurred as most of the samples and clinical re-
cords were submitted from dogs prior to this advanced disease stage.
Most samples were received for molecular studies after a clinical
diagnosis of PRA was made; the average age of the affected dogs was
3.96 1 years of age. In fact, seven dogswere older, with clinical disease not
diagnosed until 4.5-6.5 years of age. Unfortunately, based on the method
of sample acquisition and the number of different examiners involved, it
was not possible to obtainmore speciﬁc details of the age of onset for PRA.
Mapping of the PRA locus
Wecarried outGWASwith the imputed 46,063 SNPsdataset consisting
of 32 cases and 37 controls. After removing 18,679 non-informative
markers and 2 controls on the basis of the thresholds (genotyping rate
and Hardy-Weinberg equilibrium, described in the methods), 29,385
SNPs were used for genome-wide association mapping (GWAS). The
results for this ﬁrst GWAS are shown in Figure 2A. The calculated
genomic inﬂation factor (lambda) was 0.98, which does not suggest a
high stratiﬁcation. The analysis did not show any signiﬁcantly associ-
ated markers, but we detected a possible suggestive peak (max p-value
2.20x1026) on CFA15. The QQ- plot suggested a difference between
cases and controls (Figure 2B). Because of the imperfect segregation
scenario (not all the cases shared the same haplotype) we opted to select
a candidate region as the combination of the suggestive peak (log –pvalue
05) obtained by the GWAS and the homozygosity mapping. Based on
GWAS, the best eight markers were located in the same single contigu-
ous genomic region (3.43–7.93 Mb – ﬁrst marker at position 3,435,908
(CanFam2.0)) on CFA15. The possibility of a monogenic autosomal
recessive mode of inheritance was assessed by looking into the family
history of the affected dogs. A sub-population of the affected animals
could be identical by descent (IBD) for the causative variant and ﬂanking
chromosomal segments. We searched for extended regions of homozy-
gosity with simultaneous allele sharing in the merged dataset. We found
that 22 cases shared a genome region (greater than the established 1 Mb
threshold) that fulﬁlled these criteria in CFA15, a chromosome we opted
to focus on, in light of the suggestive peak detected in the GWAS. The
remaining cases were not homozygous for the CFA15 haplotype (Figure
2C, Table 1). We remapped the positions of ﬂanking markers of this
candidate region. CFA15: 3,089,722 in CanFam2.0 was remapped to
CFA15: 213,416 in CanFam3.1; while position CFA15: 7,806,737 was
remapped to CFA15: 4,796,806 (Figure 2C). The mapped critical interval
contains 102 annotated genes, 70 of which are protein coding, plus a
number of uncharacterized loci.We carefully searched the data records of
the dogs homozygous for the CFA15 haplotype and reconstructed their
family tree. The reconstructed family information and most likely com-
mon ancestors are shown in Figure 3.
Identiﬁcation of candidate causative variants
Because of the extent of the candidate region and the large number of
genes present, we opted to carry out targeted sequencing of the interval
for variant detection. Therefore, we selected six cases homozygous for
Figure 1 Fundus photographs
of the right (A, B) and left
(C, D) eyes of a 4 year old
female Miniature Schnauzer ho-
mozygous for the PPT1 complex
structural variant. Both eyes
show marked attenuation and
loss of the major and minor ret-
inal arterioles and venules, and
the optic disc is pale and under-
going atrophic changes. With
the proper angle of illumination,
there is pronounced increased
reﬂectivity from the tapetum
lucidum ( in A and D), an indi-
cation of severe retinal thinning.
The non-tapetal region shows
patches of retinal pigment epi-
thelial atrophy which appear
paler, and these are situated ad-
jacent to hyperpigmented and
darker areas (C arrows). Photo-
graphs provided by Dr. Julien
Charron, Clinique vétérinaire
Saint Roch, La Rochelle, France
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the disease-associated CFA15 haplotypes, and four controls (based on
the family information, two of these controls were obligate carriers, see
Figure 3). We detected 35 exonic variants of interest in the candidate
interval. Of these, 15 were silent. We predicted the impact of the var-
iants with the PolyPhen software (Adzhubei et al. 2010), and ex-
cluded all but two of the variants because they were predicted to be
Figure 2 Mapping. (A) Results of the genome-
wide association study (GWAS), obtained analyz-
ing the imputed Affymetrix/Illumina merged data
showing the negative log of the raw p-values
calculated with the genotypic association test
(max p-value 2.20e-06) (B) QQ-plot, showing the
observed vs. expected log p-values. The moder-
ate skewing of a marker toward the upper side
suggests a weak association with the “affected”
condition compared with what would be
expected by mere chance. (C) Result of the ho-
mozygosity mapping using the 27,061 shared
SNPs merged dataset: detail of the markers
encompassing the ﬁrst 14,490,600 Mb of
CFA15. In green the candidate region shared ex-
clusively among a sub-group of blue-marked
22 cases. Other cases (“Add”) are marked in yel-
low-orange, “Controls” in red. The region is
shown in Microsoft Excel with the different alleles
colored for ease of visualization. We opted to se-
lect a candidate region as the combination of the
suggestive peak (log –pvalue 05) obtained by the
GWAS and the homozygosity mapping.
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non-pathogenic. The two remaining, a g.339,815C . T variant in
LOC482436 (c.595C . T, p.Arg199Cys) and a g.3,209,909C . G var-
iant in the NT5C1A gene (c.41C. G, p.Pro14Arg) were subsequently
excluded as genotyping showed that they did not segregate with the
disease.
For this reason, whole genome sequencing (WGS) was carried out,
sequencing two affected animals, one obligate carrier and one control
(Figure 3). The cases were included in the targeted sequencing of the
candidate CFA15 region. The aim was to detect all the variants in the
annotated genes and loci of themapped 4.8Mb interval on CFA15, and
to potentially focus on other regions in affected dogs if detecting a
plausible causative variant in the CAF15 critical interval failed. Se-
quencing, carried out in collaboration with the Dog Biomedical Variant
Database Consortium (DBVDC), allowed us to ﬁlter and compare any
called variant with the ones present in the database, and compare its
frequency within the population of sequenced control dogs. Following
whole genome sequencing and mapping, we compared and ﬁltered
SNVs as well as small indel variants detected in the cases with the
variants in the controls and 192 publicly available dog genomes se-
quenced by DBVDC (File_S1).
Subsequently, through ﬁltering processes described above, we
identiﬁed a non-intergenic variant in our dataset that was homozy-
gous in the affected dogs. This was a single intronic variant in the
3rd intron of HIVEP3 (CFA15, g.1,432,293G. A). HIVEP3 is not,
to our knowledge, associated with retinal diseases (Hicar et al.
2001), and has low retinal expression (Unpublished information;
see below). Notably, the variants previously detected with targeted
sequencing were ﬁltered out in the WGS dataset. As we did not
consider the intronic HIVEP3 variant to be likely causative, we used
the Delly2 package in search for structural variants in the sequenced
dogs, as such variants would not have been detected by our initial
analysis pipeline. In the cases, a total of 8 deletions, 4 inversions,
9 insertions and 8 duplications were found in the critical 4.8 Mb
region. Following ﬁltering, we observed that only a single duplica-
tion was present in the homozygous state in cases, but not in con-
trols. This variant comprised a duplication of exon 5 of PPT1, in
position 2,866,454-2,877,574, CanFam3.1 (Figure 4A). Further
analysis revealed the variant to be more complex than a simple
duplication; in fact, a deletion is present within the duplicated re-
gion in which the reference 2,874,661-2,875,048 interval is deleted
(Figure 4B). Furthermore, the terminal part of the duplication had
reads that suggested an additional inversion event (File_S3). We
searched for the variant in a cohort of 192 additional control canine
genomes (File_S1) and the variant was not present in any of them.
The tpm count analysis of mRNA highlighted the different
expression levels of HIVEP3 (ENSCAFT00000004055) and PPT1
(ENSCAFT00000038806) in canine retina tissue in three independent
RNA-seq datasets comprising 27 dogs. Transcripts from both genes
were present in retina. For HIVEP3, we calculated a tpm average of
5.70 (9 samples), 2.15 (7 samples) and 7.59 (11 samples). For PPT1, we
calculated a tpm average of 161.01 (9 samples), 155.78 (7 samples) and
119.01 (11 samples). Across all the samples, PPT1 transcripts were
present at 143 transcripts per million (tpm) and thus 25 times more
abundant than HIVEP3 transcripts (5.55 tpm).
Figure 3 - Family tree of 18 Miniature Schnauzers cases affected with PRA in which there was sufﬁcient family history to identify a putative
common ancestor. Females are shown in circles, males in squares. All the animals indicated with the blue ﬁlled symbol are homozygous for the
CFA15 haplotype. Dogs indicated with an asterisk () were used in WGS. Dogs indicated with a red triangle are cases and controls subjected to
targeted sequencing. Dogs with the green tick have been conﬁrmed homozygous for the PPT1 variant through targeted or Sanger sequencing.
The blue arrow shows a conﬁrmed common ancestor for many cases, and putative carriers. The gray arrow shows another older, common ancestor
in which the carrier status is deﬁnitive.
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Figure 4 Characterization of the 11Mb-spanning variant. Figure is based on screenshots of the interval visualized with IGV. (A) Duplication of the
5th PPT1 exon visualized with IGV. The 11,120 bp duplication can be observed. From top to bottom, a case, a carrier and a control are shown.
Note the inverted pairs, marked in green by IGV, on the variant boundaries present in carrier and case. Compare the coverage of the area with the
ﬂanking regions. The blue arrows show the mutation boundaries. In the red squares, a region for each of control (), carrier () and case () is
shown. Note the heterozygous SNPs contained in the carrier interval. Additionally, compare the coverage of the carrier with the ﬂanking regions,
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Characterization of a complex structural variant
We validated the boundaries of the variant as described in the
Methods (Figure 4A, 4B). We also veriﬁed the position of the deletion
as occurring in the ﬁrst of the two duplicated segments (Figure 4C).
Furthermore, we conﬁrmed the presence of an interesting additional
element, a boundary 45 bp segment mapping on the duplication
border, exactly on the 2,877,563-2,877,607 interval. This fragment is
duplicated, and then inserted in lieu of the deleted 2,874,661-2,875,048
interval (Figure 4B, green arrowhead, File_S3). Albeit signiﬁcantly
shorter than the reference, this last feature is not a simple deletion: it
represents a conversion. In fact, an interval of nucleotides is replaced by
a sequence from elsewhere in the genome. In this speciﬁc case, our
converted fragment is inserted into the new position in amanner that is
inverted in comparison to the original sequence. Ultimately, we
deﬁned the variant with respect to the CanFam 3.1 assembly as
CFA15 g.[2,866,454_2,877,574dup; 2,874,661_2,875,048con2,877,563-
2,877,607inv], and designated the mutant allele at this variant as
PPT1dci for brevity.
We then re-evaluated the targeted sequencing data in light of the
presence of the described PPT1dci rearrangement. We conﬁrmed the
presence of the PPT1dci allele in eight dogs used for targeted sequencing:
in the six cases, the variant was homozygous, and heterozygous in the
2 obligate carriers (File_S4).
We selected two consecutive variants falling within the duplicated
interval (Figure 4B) as markers. Using the GF and GR primers, we
considered the dogs homozygous for PPT1dci only if their DNA
produced the 538 bp fragment and also were homozygous for the g.2,-
872,023delAG and g.2,872,103G. A variants. We do not consider the
presence of the 538 bp band on its own as indicative because it is visible
whether the dog is homozygous or heterozygous.
Genotyping of the variants within the population
We genotyped the HIVEP3 and PPT1dci within the population of
available Miniature Schnauzer samples. Concerning the HIVEP3
intronic variant, it was not found homozygous in any control. This
includes the controls reported above as homozygous for PPT1dci. None-
theless, the variant was absent in four of the conﬁrmed cases homozy-
gous for PPT1dci. Of these, 3 cases were heterozygous and 1 was
homozygous wild-type. The variant was also heterozygous in one ad-
ditional PRA-affected case homozygous for the CFA15 haplotype in the
homozygosity mapping. Based on these results, the HIVEP3 intronic
variant was excluded from causal association with the disease.
The disease-associated CFA15 haplotype was conﬁrmed as homo-
zygous in 22PRA affected dogs (Table 1).We added 10 additional PRA-
affected dogs from the general population to the 22 dogs described
above (therefore, 32 dogs in total). We conﬁrmed the presence of the
PPT1dci in a total of 22 cases (Table 2). Three were conﬁrmed exclu-
sively throughTargeted Sequencing. For the 10 remaining affected dogs
with the CFA15 haplotype, we did not have enough DNA to experi-
mentally conﬁrm the PPT1dci structural rearrangement (Table 2).
Of the 32 CFA15 homozygous/ PPT1dci cases described above, we
identiﬁed 26 dogs affected with PRA who were .3 years of age at the
time of the last ophthalmic examination (as reported in results; also
3 years corresponds to the lowest end of the absolute deviation from the
average time at diagnosis recorded, see Table 1).
Ontheotherhand,outof56controls, 6dogshomozygous forPPT1dci
were clinically normal (and .3 y.o.– the age range is infact between
3 and 10 years). The rest of the 50 non-affected controls used in this
study were not homozygous for PPT1dci, or for the speciﬁc CFA15
disease-associated haplotype. We detected 17 heterozygous dogs and
therefore potential carriers in the unaffected dog population.
The z-score for the association of the PPT1dci variant with the retinal
disease (26 .3 years cases vs. 6 unaffected - all homozygous - for the
variant or the haplotype) is 2.51, and the p-value of the association is 0.017.
Finally, 17 PRA cases in our dataset were not found to be not
homozygous for the PPT1dci and/or the CFA15 haplotype, or for the
HIVEP3 intronic variant, suggesting the existence of at least one addi-
tional retinal degeneration locus in the breed.
Characterization of the aberrant PPT1 transcripts
Because retinal tissues from affected dogs in pre-degenerate disease stage
were not available, we used freshly collected whole blood to characterize
the expression of the widely expressed PPT1 gene. After RNA extraction
and cDNA synthesis from the blood of one case and one control, we
designed a PCR targeting exon 4 and exon 6 of the PPT1 transcript. The
sequencing of the cloned amplicons allowed us to characterize the effect
of the variant on the mutant PPT1 transcripts. In the affected dog, we
found the presence of four different types of transcript: (I) a wild-type
transcript; (II) a mutant transcript containing a retained extra copy of
exon 5 from the duplication (c.434_537dup); (III) a longer aberrant
transcript containing a second copy of the 5th PPT1 exon, plus an addi-
tional 166 bp fragment; (IV) a longer aberrant transcript containing a
second copy of the 5th PPT1 exon, plus an additional 141 bp fragment.
Alignment of the fragments with the PPT1 reference sequence revealed
that the additional fragments in (III) and (IV) are the result of the in-
clusion of novel exons corresponding to positions chr15:2,870,731-
2,870,896 and 2,879,973-2,880,113, respectively, due to the activation
of novel cryptic splice sites (Figure 5, File S6). Due to the variability
associated with the PCR conditions and the different lengths of these
mutant transcripts, we cannot accurately quantify their presence in the
original tissue. In the control sample, we detected only the wild-type
transcript.
The resulting predicted protein sequences are reported in File_S7.
The wild type protein is predicted to be 306 amino acids long. The
duplicated exon 5 sequence (c.434_537dup) shared by all the three
mutant transcripts generates a premature stop codon and is predicted
to result in a frameshift and identical truncated translation products, p.
(Arg180CysfsTer14). We did not experimentally assess whether this
truncated protein is truly expressed.
DISCUSSION
A coding PPT1 variant as a suitable candidate for PRA
In this paper, we provide evidence that homozygosity for the PPT1dci
allele is strongly associated with PRA in theMiniature Schnauzer breed,
and note the greater coverage of the case in comparison to carrier and control. (B) Critical regions of the variant. The blue arrows show the
mutation boundaries (g.2866454_2877574dup), the red arrows the conversion (g.2874661_2875048con2,877,563-2,877,607inv). In detail, the
green interval represents the 45 bp interval (2,877,563-2,877,607) duplicated, inverted and inserted in position g.2874661_2875048 in lieu of
the bases normally present in such interval. Details for the sequencing primers are shown in File_S2. (C) Representation of the variant – top, the
wild type (Wt), bottom the duplication (Mu). Observe the gap region (in red in the reference) missing in the ﬁrst copy, substituted by an inserted
and inversed copy of the 45 bp interval (2,877,563-2,877,607), shown as a green arrowhead. Primer placement for the long-range PCR is shown:
on the right, the long PCR products obtained (1 and 2 are shown run on a 1% agarose gel, along with the ladder (Mk). See also File_S2.
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and we refer to the disease as PRAPPT1. The use of GWAS and homo-
zygosity mapping in combination with whole genome sequencing en-
abled us to identify a suitable candidate region. Access to sequenced
genomes through the Dog Biomedical Variant Database Consortium
(DBVDC) was imperative in the ﬁltering and the proper selection of
disease-associated variants, signiﬁcantly reducing the number of vari-
ants falling within the candidate CFA15 region that required testing for
the association. We identiﬁed a duplication encompassing roughly 11 kb
on CFA15, which later revealed to be the more complex PPT1dci.
Of the 51 cases of PRA studied that were wildtype for the Type A
PRA (RPGR) variant, the disease-associated CFA 15 haplotype was
homozygous in 32 PRA affected dogs. We conﬁrmed the presence of
the PPT1dci allele in 22 of them, but for the remaining 10, we did not
have enough DNA to experimentally conﬁrm the structural rearrange-
ment. Six non-affected dogs were homozygous for the PPT1dci variant,
and four of them were examined above the average age of diagnosis for
the disease.
Another candidate variant that was initially considered is the
HIVEP3 CFA15 intronic variant, g.1,432,293G . A. The HIVEP
proteins represent a group of polypeptides which are studied for their
roles in the regulation of an assortment of genes, including those encod-
ing collagen type IIA, aA-crystallin and b-interferon (Hicar et al.
2001). To our knowledge, HIVEP3 is not associated with retinal disor-
ders and retinal metabolism, nor does it have any known role in retinal
structure or function. Additionally, by analyzing the tpm of the tran-
scripts of both genes in three different datasets, we found that PPT1
transcripts are 25 times more abundant compared to HIVEP3. The
HIVEP3 intronic variant has been found heterozygous (3 times) or wild
type (1 time) in four cases homozygous for the PPT1dci variant. Fur-
thermore, it was found heterozygous in a ﬁfth unconﬁrmed case ho-
mozygous for the CFA15 haplotype.
PPT1dci is (I) the only homozygous variant occurring in all the PRA
cases homozygous for the CFA15 haplotype; (II) involves a gene known
to have a role in (syndromic) retinal degeneration in dog and other
species; and (III) is shown to be highly expressed in retina compared to
HIVEP3. Therefore, we propose the PPT1dci variant as causative for
PRA in Miniature Schnauzer. Due to the presence of six clinically
normal homozygous mutant dogs, we postulate incomplete penetrance
of the phenotype for the variant. This hypothesis is consistent with the
non-syndromic nature of the retinal disease.
The presence of the HIVEP3 variant in heterozygosity in a homo-
zygous interval is unexpected.-Nonetheless, the lack of perfect segrega-
tion between the two variants suggests that a recombination probably
occurred in a previous generation. Cases with similar discrepancies
(perhaps suggesting a different explanation such as additional gene
conversion events, or even potential revertation mutations) are not
unheard of and have previously been reported (Gerber et al. 2015). It
is also possible that the lack of higher density SNP information pre-
vented us from discerning what are in fact two different haplotypes in
the acrocentric region of CFA15.
Role of PPT1 in retinal degeneration
The PPT1 gene encodes for palmitoyl-protein thioesterase 1 (PPT1), a
small glycoprotein and lysosomal hydrolase that catalyzes the removal
of palmitate from its thioester linkage to serine residues in S-acylated
n Table 2 Summary table of genotyping results for PPT1dci.
Affected and unaffected dogs homozygous and heterozygous for
the haplotype and the PPT1dci variant are shown





Targeted Sequencing only 3
PRA Affected, CFA15 haplotype
but not genotyped for PPT1
10
PPT1dci Unaffected by PRA 6
Carriers conﬁrmed in the sample
population (total)
11
-insufﬁcient DNA for genotyping
Figure 5 - Characterization of the transcripts. (A)
PCR carried out with the 4F and 6R primers shown
in File_S2. On the gel, is shown the ladder (Mk),
RT-PCR of the blood cDNA extracted from one
affected individual (A) is shown along with PCR
obtained from the control (C). A schematic of (I)
the wild-type transcript, wt; (II) a mutant transcript
containing a retained exon 5 from the duplication
(that is, containing thus two copies of the 5th PPT1
exon),mut 1; (III) a third, longer transcript contain-
ing a second copy of the 5th PPT1 exon plus an
additional 166 bp fragment, mut2; (IV) a fourth,
aberrant transcript containing a second copy of
the 5th PPT1 exon plus an additional 141 bp frag-
ment, mut3. The asterisk shows the common pre-
mature stop codon in the additional exon 5. (B)
Localization on the reference sequence (included
an IGV screenshot of the interval) of the C1 and
C2 novel exons, in position c.2,870,731-
2,870,896 (C1) and 2,879,973-2,880,113 (C2),
respectively.
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proteins. PPT1 has been localized to lysosomes in some cell types
(Hellsten et al. 1996). However, Heinonen and colleagues suggested
that PPT1 may not exclusively be a lysosomal hydrolase, and that the
speciﬁc targeting of PPT1 into the neuritic shafts and nerve terminals
indicates that PPT1may be associatedwith themaintenance of synaptic
function as well. They also suggested the presence of an extracellular
substrate for PPT1 (Heinonen et al. 2000). In murine primary neurons
and brain tissue, PPT1 is localized in synaptosomes and synaptic ves-
icles but not in lysosomes, and, as such, abnormal synaptic functioning
could play a role in the CLN1 form of neuronal ceroid lipofuscinosis
(Lehtovirta 2001). Thus, it appears that PPT1 may play a different role
in different cell types.
Homozygosity in over 80 variants in human PPT1 result in the
CLN1 form of neuronal ceroid lipofuscinosis (NCL), a progres-
sive early onset neurodegenerative disease (http://www.ucl.ac.uk/ncl/
CLN1mutationtable.htm). NCL associated with PPT1 variants have
also been reported in dogs (Sanders et al. 2010; Kolicheski et al.
2017). NCLs are a group of inherited lysosomal storage disorders,
characterized by progressive neurodegeneration, including progressive
retinal degeneration, and by the accumulation of autoﬂuorescent lyso-
somal storage granules in the CNS and other tissues (Bennett and
Hofmann 1999). In CLN1 disease, existence of a positive feedback loop
has been proposed, where palmitoylation of PPT1 results in decreased
activity and a subsequent elevation in the amount of palmitoylated
proteins occurs. Such feedback is likely to initiate a vicious cycle that
ultimately enhances NCL progression (Segal-Salto et al. 2016).
In humans, NCL-associated PPT1 genetic variants vary in nature
and position. Of 61 genetic variants analyzed, these ranged from mis-
sense (n = 27), nonsense (11), splice-site (10), insertions (4), deletions
(6), insertion-deletion (1), one that could be either missense or splice-
site affecting, and one variant affecting the initiator methionine (Kousi
et al. 2011). Disease causing variants have been identiﬁed in each of the
nine exons in humans. There is a correlation between the nature of the
genetic variant and the sub-type of CLN1. In fact, combinations of
nonsense or frameshift alleles result in an infantile onset phenotype
with disease onset at less than 2 years and rapid progression (Das et al.
1998; Das et al. 2001). Overall, PPT1 variants causing the more severe
infantile and late infantile NCLs are located closer to the catalytic triad
(Ser 115, Asp 233 andHis 289) (Bellizzi et al. 2000; Das et al. 2001), and
cause the most drastic reduction of the enzyme activity. In contrast,
variants associated with later disease onset NCL are located further
from the catalytic triad and predicted to cause less dramatic changes
to secondary and tertiary structure of the protein (Das et al. 2001).
Reports of milder phenotypes associated withmissense variants suggest
the use of alternative sorting pathways for PPT1, or the possibility that
mutant PPT1 molecules show a higher degree of oligomerization,
possibly as an attempt to regulate activation and/or transport of the
enzyme (Lyly et al. 2007).
In mice, knockdown of Ppt1 leads to spasticity and motor abnor-
malities, leading to death by 10 months of age (Gupta et al. 2001).
Deletion of exon 4 replicates infantile NCL, and homozygous mutant
mice show loss of vision from 8 weeks of age, seizures after 4 months
and paralysis of hind limbs starting at 5 months (Jalanko et al. 2005).
Mice with an inserted premature stop codon in exon 5 show hindlimb
spasticity and granular osmiophilic deposits in brain and spleen, along
with retinal degeneration (Bouchelion et al. 2014). Similarly, PPT1
genetic variants in dog are also associated with neurologic abnormal-
ities and blindness. In the Dachshund and Cane Corso breeds, a
homozygous 1 bp insertion in exon 8 or a homozygous splicing site
variant affecting exon 1, respectively, result in neurologic disease and
early onset blindness (Sanders et al. 2010; Kolicheski et al. 2017).
Based on the association between PPT1 genetic variants andNCL in
patients and animal models, how can we explain the non-syndromic
nature of the retinal disease in Miniature Schnauzer dogs with the
complex PPT1 exon 5 duplication variant? We hypothesize that this
results from the high demand for rhodopsin (Rh) palmitoylation in the
retina, and the presence of wild type mRNA that fulﬁlls the needs for
this enzyme in non-retinal tissues (Xiong and Bellen 2013). After all,
heterozygous PPT1 carriers, either human or animals, are normal in
terms of neurologic function and vision (Sanders et al. 2010; Kousi et al.
2011; Kolicheski et al. 2017). The expression analysis on RNA isolated
from peripheral white blood cells demonstrated that a proportion of
PPT1wildtype transcripts, in addition to three aberrant transcripts, was
present. This suggests that the variant, albeit spanningmore than 11 kb,
does not completely impede the expression of a wild type protein.
In the retina, Rh is subjected to a number of post-translational
modiﬁcations (St Jules et al. 1990) of which cysteine S-palmitoylation is
crucial for its biological function; depalmitoylation has been shown
to inhibit Rh regeneration, and to increase its ability to activate
transducin’s light-dependent GTPase activity (Morrison et al. 1991). Pal-
mitoylated Rh can acquire raftophilicity upon G protein-stabilized dimer-
ization, and thereby organize receptor-cluster rafts by recruiting raftophilic
lipids, ultimately initiating the phototransduction cascade in rod photore-
ceptors (Seno and Hayashi 2017). There is evidence of cross-talk between
the autophagic and endosomal/lysosomal pathways. In Drosophila, it has
been shown that degradation of Rhodopsin 1 occurs via cross-talk between
the autophagy and endosomal degradation pathways, and that autophagy
acts as a compensatory pathway when the endosomal/lysosomal pathway
is impaired (Midorikawa et al. 2010; Seno and Hayashi 2017). The study
also indicated that Ppt1 is essential for photoreceptor viability inDrosoph-
ila, and Ppt1 mutants show light- dependent retinal degeneration second-
ary to intracellular accumulation of rhodopsins from Ppt1 disruption.
A similar ﬁnding of non-syndromic retinal disease, either isolated
macular degeneration or widespread generalized retinal disease, has
been reported in patients with the CLN7/MSFD8 form of NCL. Differ-
ent genetic variants in the gene were found and some were considered
’mild’ or ’moderate’ disease alleles. There were even patients who were
affected with non-syndromic retinal disease when a null variant allele
was present. In fact, as an example, in a previous study concerning
predictive analyses of pathogenicity scores of variants on protein se-
quence, the authors found no correlation between the impact of the
different variants and whether patients would develop non-syndromic
retinal disease or NCL (Khan et al. 2017).
In regard to a possible late-onset neurologic disease in older dogs
homozygous for PPT1 variants, we were able to contact owners as well
as referring veterinarians and follow up ﬁve older dogs homozygous for
the PPT1 complex variant and affected with PRAPPT1. These dogs were
alive at the time, or had died from unrelated diseases (e.g., heart failure).
At ages ranging from 6-8 years, these dogs did not show any neuro-
logical disease. We do not possess data that is able to support a com-
plete hypothesis regarding why PPT1dci has a retina-speciﬁc effect.
However, we can speculate that the rate of outer segment (rhodopsin)
turnover in retina could have a speciﬁc role, and the variant would
affect the amount of the expression only on a level affecting the spe-
ciﬁc tissue with high requirements for palmitoylation, such as the retina
(Aguirre and O’Brien 1986; Wetzel et al. 1989; St Jules et al. 1990; Katz
et al. 1999); for this reason, the presence of the wild-type transcript
would lead to a phenotype milder on a general level, explaining the
non-syndromic nature of the disease.
Following a similar line of reasoning, we could suggest that the
healthy dogs homozygous for the risk allele might produce a greater
amount of wild-type transcript, or possibly a greater amount of such
Volume 9 February 2019 | PPT1 Variant in Dog Retinal Degeneration | 435
transcript is translated due to internal factors, such as the modulating
inﬂuence of additional genetic variants in cis or in trans (Schubert et al.
1997; Raj et al. 2010; Cooper et al. 2013). The individual differences de-
scribed above could explain the incomplete penetrance of the retinal disease.
In summary, our studies conﬁrm a complex structural PPT1 variant
associated with a non-syndromic canine retinal degeneration (PRAPPT1).
The characterization of the variant through whole genome and Sanger
sequencing helped to identify a complex variant involving instances of
duplication, deletion and re-insertion of a duplicated 45 bp fragment in a
non-adjacent region. This genetic variant accounts for 63% of Minia-
ture Schnauzers affected with retinal degeneration in which the Type A
form of the disease has been excluded, which indicates that at least one
additional retinal disease locus exists in the breed.
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